OCLN and leiomyosarcoma: For example, unequivocal occludin staining was identified in 34.7% (9.7% strong) of Hodgkin’s lymphomas, 47.1% (18.8%) of Ewing sarcomas, 6.9% (2.3%) of leiomyosarcomas, and in 10.5% (5.3%) of osteosarcomas.